Month: April 2019

Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of better biomarkers based on genome / exome profiles. Novel biomarkers, such as tumour mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumour infiltrating lymphocytes (TILs) and certain others, are presently being investigated across

Studies suggest that each prescription drug requires around 10 years and over USD 2.5 billion in working capital before it reaches the market. Further, it is estimated that, in the US, 40% of the pharma industry’s R&D budget is spent solely on conducting clinical trials. Estimates suggest that nearly 85% of Novel Clinical trials fail

It has been estimated that over 300 million people (considering all age groups) suffer from depression worldwide. Depressive disorders are estimated to be responsible for an economic burden of up to USD 210 billion per year in the US. Since the 1950s, around 30 branded drugs and more than 150 generic products have been approved

It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. It is also worth highlighting that companion diagnostics (CDX) guided drug development efforts have been estimated to help reduce clinical trial costs by almost 60%. Since the approval of the HercepTest (in 1998) for identifying patients for treatment

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the biopharmaceutical CMOs in this domain. It is worth highlighting that, since 2000, more than 115